REG - Oxford Biomedica PLC - Director Shareholding <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

29/04/2016 13:40

RNS Number : 8646W
Oxford Biomedica PLC
29 April 2016
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 29 April 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 29 April 2016 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
Interest after purchase
Director / PDMR
Title
Price per share (p)
Number of Ordinary Shares acquired
Number of Ordinary Shares
% of total
issued share capital
Peter Nolan
Executive director
5.5567p
359,925
1,401,968
0.05%
The issued share capital of the Group is 2,702,901,494 1p ordinary shares.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica has built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUKOURNOASUAR